HC Wainwright Has Positive Outlook of MNPR FY2027 Earnings

Key Points

• HC Wainwright nudged its FY2027 EPS estimate for Monopar Therapeutics to ($1.35) from ($1.37) and maintained a Buy rating with a $125 price target.
• Other analysts were generally upbeat as well, with BTIG raising its target to $117, UBS setting $125, and the overall consensus remaining a Buy with a $112.08 target.
• Monopar shares were trading at $105.70, near their 1-year high of $116.64, after the company recently reported a smaller-than-expected quarterly loss of ($0.46) EPS versus the ($0.87) estimate.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Investment analysts at HC Wainwright increased their FY2027 earnings per share estimates for Monopar Therapeutics in a research note issued on Wednesday, July 22nd. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($1.35) for the year, up from their previous estimate of ($1.37). HC Wainwright has a "Buy" rating and a $125.00 price target on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($2.82) per share. HC Wainwright also issued estimates for Monopar Therapeutics' FY2028 earnings at $0.91 EPS, FY2029 earnings at $2.41 EPS and FY2030 earnings at $6.61 EPS.

A number of other analysts also recently issued reports on the stock. BTIG Research increased their price target on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. Zacks Research raised shares of Monopar Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Monday, July 13th. Wall Street Zen downgraded shares of Monopar Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, July 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Finally, UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research note on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $112.08.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $105.70 on Friday. The firm has a market cap of $708.19 million, a price-to-earnings ratio of -55.63 and a beta of 1.46. The company has a 50 day moving average price of $79.49 and a 200-day moving average price of $66.36. Monopar Therapeutics has a 1-year low of $29.18 and a 1-year high of $116.64.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.41.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. purchased a new stake in Monopar Therapeutics in the 3rd quarter worth $28,000. BNP Paribas Financial Markets raised its position in Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock worth $57,000 after acquiring an additional 349 shares during the period. Meeder Asset Management Inc. purchased a new position in Monopar Therapeutics during the fourth quarter valued at $65,000. JPMorgan Chase & Co. lifted its holdings in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Monopar Therapeutics in the second quarter valued at about $80,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.